1277 related articles for article (PubMed ID: 23606509)
1. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
3. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
4. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
5. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy can increase circulating endothelial progenitor cell number in men with late onset hypogonadism.
Liao CH; Wu YN; Lin FY; Tsai WK; Liu SP; Chiang HS
Andrology; 2013 Jul; 1(4):563-9. PubMed ID: 23653307
[TBL] [Abstract][Full Text] [Related]
7. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
8. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
Moisey R; Swinburne J; Orme S
Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
[TBL] [Abstract][Full Text] [Related]
9. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
10. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
11. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
Mulhall JP; Valenzuela R; Aviv N; Parker M
Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
[TBL] [Abstract][Full Text] [Related]
13. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
[TBL] [Abstract][Full Text] [Related]
14. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
16. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
18. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
[TBL] [Abstract][Full Text] [Related]
19. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
Yassin AA; Saad F
J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]